2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Sunday, November 10, 2019

4:30PM-6:00PM: Abstract Number: 952

Rate of Thirty-Day Readmissions in Systemic Lupus Erythematosus Rivals Congestive Heart Failure and Exceeds the General Medicare Population

3S089: Health Services Research I: Clinical Perspectives (951–956)

4:30PM-6:00PM: Abstract Number: 935

Reduction of Anterior Uveitis Flares in Patients with Axial Spondyloarthritis Following 1 Year of Treatment with Certolizumab Pegol: 48-Week Interim Results from a 96-Week Open-Label Study

3S111: Spondyloarthritis Including Psoriatic Arthritis – Clinical II: Axial Spondyloarthritis Treatment (933–938)

4:30PM-6:00PM: Abstract Number: 948

Relapsing Cryoglobulinemic Vasculitis Following Successful HCV Eradication by Interferon-Free Direct Acting Antivirals, an International Multicenter Study

3S112: Vasculitis – Non-ANCA-Associated & Related Disorders I: Miscellaneous Disorders (945–950)

4:30PM-6:00PM: Abstract Number: 940

Response to Placebo in Randomized Clinical Trials with Biologics in Non-renal, Non-neuropsychiatric Systemic Lupus Erythematosus: A Systematic Review and Pooled Analysis

3S110: SLE – Clinical III: Clinical Trials II (939–944)

4:30PM-6:00PM: Abstract Number: 906

Sarcoidosis as a Systemic Disease. Clinical and Epidemiological Characterization of Systemic Phenotype in 1521 Patients

3S104: Miscellaneous Rheumatic & Inflammatory Disease I: Expanding the Spectrum of Clinical Features in Rheumatological Disorders (903–908)

4:30PM-6:00PM: Abstract Number: 901

Sensitivity of Dual-Energy CT, Ultrasound, and X-Ray for Pseudogout: A Pilot Study

3S102: Metabolic & Crystal Arthropathies I: Clinical (898–902)

4:30PM-6:00PM: Abstract Number: 882

Serum Anti-Vimentin Autoantibodies May Uniquely Predict Response to Therapy in Lupus Nephritis

3S100: B Cell Biology & Targets in Autoimmune & Inflammatory Disease (880–885)

4:30PM-6:00PM: Abstract Number: 900

Serum Urate Lowering with Allopurinol Improves Endothelial Function in Young Adults

3S102: Metabolic & Crystal Arthropathies I: Clinical (898–902)

4:30PM-6:00PM: Abstract Number: 917

Systemic Juvenile Idiopathic Arthritis-Lung Disease: Characterization and Risk Factors

3S107: Pediatric Rheumatology – Clinical I: Systemic JIA (915–920)

4:30PM-6:00PM: Abstract Number: 902

The Effects of a Low-Fat, Mediterranean, or Low-Carbohydrate Diet on Serum Urate

3S102: Metabolic & Crystal Arthropathies I: Clinical (898–902)

4:30PM-6:00PM: Abstract Number: 914

The Effects of Vitamin D and Marine Omega-3 Fatty Acid Supplementation on Chronic Knee Pain in Older U.S. Adults

3S106: Osteoarthritis – Clinical I: Innovations (909–914)

4:30PM-6:00PM: Abstract Number: 956

The Impact of Psychiatric Comorbidity on Health Care Utilization and Preventive Health Care in Rheumatoid Arthritis: A Population Based Study

3S089: Health Services Research I: Clinical Perspectives (951–956)

4:30PM-6:00PM: Abstract Number: 893

The Presence of Extractable Nuclear Antigens (ENA) Antibodies in a Large Population-based Cohort from the Netherlands and Their Association with Known Risk Factors for Systemic Lupus Erythematosus and Primary Sjögren Syndrome

3S101: Epidemiology & Public Health II: SLE (892–897)

4:30PM-6:00PM: Abstract Number: 885

TLR9 Signaling in HCV-Associated Atypical Memory B Cells Triggers Th1 and Rheumatoid Factor Autoantibody Responses

3S100: B Cell Biology & Targets in Autoimmune & Inflammatory Disease (880–885)

4:30PM-6:00PM: Abstract Number: 947

TNF Inhibitor Treatment and Dramatic Stroke Risk Reduction in Patients with Deficiency of Adenosine Deaminase 2

3S112: Vasculitis – Non-ANCA-Associated & Related Disorders I: Miscellaneous Disorders (945–950)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at abstracts@rheumatology.org.